Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Colorcon
Medtronic
AstraZeneca
Merck

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

ALIMTA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Alimta patents expire, and what generic alternatives are available?

Alimta is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has eighteen patent family members in eleven countries.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pemetrexed disodium profile page.

Drug patent expirations by year for ALIMTA
Drug Prices for ALIMTA

See drug prices for ALIMTA

Generic Entry Opportunity Date for ALIMTA
Generic Entry Date for ALIMTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALIMTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, San FranciscoPhase 2
John Wayne Cancer InstitutePhase 1

See all ALIMTA clinical trials

Recent Litigation for ALIMTA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Eli Lilly and Company v. Eagle Pharmaceuticals, Inc.2017-09-11
ELI LILLY AND COMPANY v. HOSPIRA, INC.2016-12-21
ELI LILLY AND COMPANY v. DR. REDDY'S LABORATORIES, LTD.2016-02-05

See all ALIMTA litigation

PTAB Litigation
PetitionerDate
Apotex Inc.2016-07-14
Wockhardt Bio AG2016-07-08
Apotex Inc.2016-07-01

See all ALIMTA litigation

Pharmacology for ALIMTA

US Patents and Regulatory Information for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007   Start Trial   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004   Start Trial   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007   Start Trial   Start Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALIMTA
Drugname Dosage Strength RLD Date
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe   Start Trial
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe   Start Trial
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe   Start Trial
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe   Start Trial

Supplementary Protection Certificates for ALIMTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677 7/2005 Austria   Start Trial PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
0432677 SPC/GB05/011 United Kingdom   Start Trial PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Baxter
Johnson and Johnson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.